Session » (1592–1611) Vasculitis – ANCA-Associated Poster II

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1609

A Multicenter Prospective Longitudinal Observational Study To Determine Safety Of Extended Treatment With Rituximab In Maintaining Remission In Patients With ANCA Associated Vasculitis (AAV) – An Interim Analysis

10:30AM-12:30PM: Abstract Number: 1607

Antibiotic Prophylaxis during Treatment of ANCA-associated Vasculitis with Rituximab: Data from a Multicenter Cohort

10:30AM-12:30PM: Abstract Number: 1602

Biomarkers of Innate Immune Activation to Identify Non-Response to Rituximab in Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1605

Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study

10:30AM-12:30PM: Abstract Number: 1593

Comparison of rituximab induction and maintenance regimens in ANCA-associated vasculitis: PK/PD modelling approach in real-world patients

10:30AM-12:30PM: Abstract Number: 1599

Cyclophosphamide versus Rituximab in the treatment of Anca-associated Vasculitis: Adverse events and Relapses

10:30AM-12:30PM: Abstract Number: 1610

Early Mepolizumab Initiation Enables High Glucocorticoid and Immunosuppressant Discontinuation Rates in EGPA: A Retrospective Cohort Study of 35 Patients

10:30AM-12:30PM: Abstract Number: 1597

Effectiveness and Safety of Rituximab Biosimilars in Small Vessel Vasculitis: a Systematic Literature Review

10:30AM-12:30PM: Abstract Number: 1611

Effectiveness of Avacopan and Its Impact on Serum Calprotectin in MPA/GPA Patients Receiving Rituximab-Based Remission Induction: A Single-Center Study

10:30AM-12:30PM: Abstract Number: 1608

Efficacy of Anti-IL-5/R Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1596

GPA-Associated Tracheobronchial Stenosis: Immunosuppressant Use and Dilation Frequency

10:30AM-12:30PM: Abstract Number: 1604

Impact and risk factors of anti-rituximab antibodies in small-vessel vasculitis: a multicenter retrospective study

10:30AM-12:30PM: Abstract Number: 1592

Mepolizumab to Benralizumab Switch in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

10:30AM-12:30PM: Abstract Number: 1601

Obinutuzumab Induces and Maintains Remission in Refractory or Relapsing ANCA-Associated Vasculitis – A Case Series

10:30AM-12:30PM: Abstract Number: 1606

One Year Real-World Effectiveness with Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Large Healthcare System

10:30AM-12:30PM: Abstract Number: 1600

Real-world clinical effectiveness of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis: a National multicenter study

10:30AM-12:30PM: Abstract Number: 1603

SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement

10:30AM-12:30PM: Abstract Number: 1595

Subcordal Stenosis is a Glucocorticoid-Responsive Manifestation of Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1594

Two-Year Efficacy of Anti-Interleukin-5/Receptor Therapies According to Anti-Neutrophil Cytoplasmic Antibodies Status in Patients with Eosinophilic Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1598

Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].